179 related articles for article (PubMed ID: 2851677)
1. Antihypertensive action of a new angiotensin converting enzyme inhibitor, (R)-3-[(S)-1-carboxy-5-(4-piperidyl)pentyl]amino-4-oxo-2,3,4,5-tetr ahy dro-1,5-benzothiazepine-5-acetic acid (CV-5975), in various hypertensive models.
Inada Y; Tanabe M; Kawazoe K; Nishikawa K
Jpn J Pharmacol; 1988 Jul; 47(3):311-22. PubMed ID: 2851677
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of angiotensin converting enzyme by (R)-3-[(S)-1-carboxy-5-(4-piperidyl)pentyl]amino-4-oxo-2,3,4,5-tetra- hydro-1,5-benzothiazepine-6-acetic acid (CV-5975), a non-sulfhydryl compound.
Inada Y; Tanabe M; Itoh K; Sugihara H; Nishikawa K
Jpn J Pharmacol; 1988 Nov; 48(3):323-30. PubMed ID: 2851678
[TBL] [Abstract][Full Text] [Related]
3. Antihypertensive action of a non-sulfhydryl angiotensin converting enzyme inhibitor (CV-3317) in various hypertensive models.
Inada Y; Tanabe M; Shibouta Y; Kawazoe K; Nishikawa K; Kikuchi S
Jpn J Pharmacol; 1986 Sep; 42(1):1-8. PubMed ID: 3025485
[TBL] [Abstract][Full Text] [Related]
4. (R)-3-[(S)-1-carboxy-5-(4-piperidyl)pentyl]amino-4-oxo-2,3,4,5- tetrahydro-1,5-benzothiazepine-5-acetic acid (CV-5975): a new potent and long-lasting inhibitor of angiotensin converting enzyme.
Inada Y; Itoh K; Kamiya K; Sugihara H; Nishikawa K
Jpn J Pharmacol; 1988 Jun; 47(2):135-41. PubMed ID: 3199591
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the antihypertensive effects of the new angiotensin II (AT1) receptor antagonist candesartan cilexetil (TCV-116) and the angiotensin converting enzyme inhibitor enalapril in rats.
Wada T; Inada Y; Ojima M; Sanada T; Shibouta Y; Nishikawa K
Hypertens Res; 1996 Jun; 19(2):75-81. PubMed ID: 10968199
[TBL] [Abstract][Full Text] [Related]
6. Antihypertensive properties of a new long-acting angiotensin converting enzyme inhibitor in renin-dependent and independent hypertensive models.
Nagata S; Takeyama K; Fukuya F; Nagai R; Hosoki K; Nishimura K; Deguchi T; Karasawa T
Arzneimittelforschung; 1995 Aug; 45(8):853-8. PubMed ID: 7575746
[TBL] [Abstract][Full Text] [Related]
7. [Antihypertensive activity of the angiotensin converting enzyme inhibitor quinapril HCl: (S)-2-[(S)-N-[(S)-1-ethoxycarbonyl-3-phenylpropyl) alanyl]-1,2,3,4- tetrahydro-3-isoquinolinecarboxylic acid monohydrochloride in various hypertensive animal models].
Yaoka O; Aoki K; Nakajima T; Setoguchi M
Nihon Yakurigaku Zasshi; 1993 Jul; 102(1):35-45. PubMed ID: 8335286
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological studies on (4S)-1-methyl-3-[(2S)-2-[N-((1S)-1-ethoxycarbonyl-3-phenylpropyl)amino] propionyl]-2-oxo-imidazolidine-4-carboxylic acid hydrochloride (TA-6366), a new ACE inhibitor: I. ACE inhibitory and anti-hypertensive activities.
Kubo M; Kato J; Ochiai T; Ishida R
Jpn J Pharmacol; 1990 Jun; 53(2):201-10. PubMed ID: 2200918
[TBL] [Abstract][Full Text] [Related]
9. Effects of an angiotensin-converting enzyme (ACE) inhibitor, SA446, on tissue ACE activity in normotensive, spontaneously hypertensive, and renal hypertensive rats.
Nakata K; Nishimura K; Takada T; Ikuse T; Yamauchi H; Iso T
J Cardiovasc Pharmacol; 1987 Mar; 9(3):305-10. PubMed ID: 2437397
[TBL] [Abstract][Full Text] [Related]
10. Antihypertensive activity of alacepril, an orally active angiotensin converting enzyme inhibitor, in renal hypertensive rats and dogs.
Takeyama K; Minato H; Fukuya F; Kawahara S; Hosoki K; Kadokawa T
Arzneimittelforschung; 1985; 35(10):1502-7. PubMed ID: 3000389
[TBL] [Abstract][Full Text] [Related]
11. Effects of omapatrilat in low, normal, and high renin experimental hypertension.
Trippodo NC; Robl JA; Asaad MM; Fox M; Panchal BC; Schaeffer TR
Am J Hypertens; 1998 Mar; 11(3 Pt 1):363-72. PubMed ID: 9544878
[TBL] [Abstract][Full Text] [Related]
12. Effects of enalapril on the expression of cardiac angiotensin-converting enzyme and angiotensin-converting enzyme 2 in spontaneously hypertensive rats.
Yang Z; Yu X; Cheng L; Miao LY; Li HX; Han LH; Jiang WP
Arch Cardiovasc Dis; 2013 Apr; 106(4):196-201. PubMed ID: 23706365
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the actions of the angiotensin-converting enzyme inhibitors enalapril and S-9490-3 in sodium-deplete and sodium-replete spontaneously hypertensive rats.
DiNicolantonio R; Doyle AE
J Cardiovasc Pharmacol; 1985; 7(5):937-42. PubMed ID: 2413304
[TBL] [Abstract][Full Text] [Related]
14. Hypotensive and hemodynamic effects of the new non-sulfhydryl angiotensin converting enzyme inhibitor N-[8-amino-1(S)-carboxyoctyl]-L-alanyl-L-proline.
Shirota M; Iijima M; Ushijima T; Kajiwara Y; Kitabatake K
Arzneimittelforschung; 1990 Dec; 40(12):1303-9. PubMed ID: 2095126
[TBL] [Abstract][Full Text] [Related]
15. Antihypertensive action of the novel angiotensin converting enzyme inhibitor benazepril hydrochloride in hypertensive rat models.
Tanaka M; Yamamoto S; Nakao K; Inukai T; Ogawa N; Katsumura H; Ohara N; Shukunobe K; Ono H
Arzneimittelforschung; 1991 Jun; 41(6):608-12. PubMed ID: 1930348
[TBL] [Abstract][Full Text] [Related]
16. Long-lasting hypotensive and antihypertensive effects of a new 1,5-benzothiazepine calcium antagonist in hypertensive rats and renal hypertensive dogs.
Narita H; Murata S; Yabana H; Kikkawa K; Sugawara Y; Akimoto Y; Nagao T
Arzneimittelforschung; 1988 Apr; 38(4):515-20. PubMed ID: 3041970
[TBL] [Abstract][Full Text] [Related]
17. Antihypertensive action of a novel orally active angiotensin converting enzyme inhibitor altiopril calcium (MC-838) in several hypertensive models of rats: comparison with captopril.
Aono J; Koga T; Yamazaki T; Shiraki Y; Sakai K
Arch Int Pharmacodyn Ther; 1988; 292():203-22. PubMed ID: 3293542
[TBL] [Abstract][Full Text] [Related]
18. Dual inhibition of angiotensin converting enzyme and neutral endopeptidase produces effective blood pressure control in spontaneously hypertensive rats.
Kostova E; Jovanoska E; Zafirov D; Jakovski K; Maleska V; Slaninka-Miceska M
Bratisl Lek Listy; 2005; 106(12):407-11. PubMed ID: 16642666
[TBL] [Abstract][Full Text] [Related]
19. Moexipril, a new angiotensin-converting enzyme (ACE) inhibitor: pharmacological characterization and comparison with enalapril.
Edling O; Bao G; Feelisch M; Unger T; Gohlke P
J Pharmacol Exp Ther; 1995 Nov; 275(2):854-63. PubMed ID: 7473177
[TBL] [Abstract][Full Text] [Related]
20. Reducing blood pressure in SHR with enalapril provokes redistribution of NHE3, NaPi2, and NCC and decreases NaPi2 and ACE abundance.
Yang LE; Leong PK; McDonough AA
Am J Physiol Renal Physiol; 2007 Oct; 293(4):F1197-208. PubMed ID: 17652375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
